BOCA RATON, Fla. – Research has revealed new benefits from a novel treatment for depression.
A recent study published in the Journal Nature investigating Ketamine, a drug used for years in anesthesia.
The study in mice found that clinical use of the drug appears to provide long last relief from depressive symptoms.
“So, Ketamine, at a basic level, causes certain neurochemical changes but really the downstream effects of the neurochemical changes that it induces really promotes brain neuroplasticity and actually has neuroprotective effects,” said psychiatrist Dr. Gil Lichtshein.
Lichtshein said the study showed that the therapeutic effect of Ketamine outweighs any potential side effects, when properly administered.
INCREASE IN REPORTS OF CHRONIC FATIGUE SYNDROME
A survey by the CDC found that chronic fatigue syndrome or CFS may be more common than previously thought.
According to the survey, an estimated 4.3 million Americans said their doctor told them they have CFS, which is far above the agency’s previous estimate of 836,000.
CFS is generally characterized by at least six months of profound tiredness.
The rise in cases may be partially attributed to Long Covid.
One international study found that nearly 90 percent of respondents who had not recovered from Long Covid reported chronic fatigue.
The CDC also reported that about 90 percent of people with the condition have not been diagnosed.